Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Clinical Trials, Phase II as Topic
  • Disease Progression
  • Drug Resistance, Neoplasm*
  • Female
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Mutation*
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Risk
  • Sulfonamides / pharmacology*

Substances

  • Antineoplastic Agents
  • BCL2 protein, human
  • Bridged Bicyclo Compounds, Heterocyclic
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • venetoclax